病例报告:CCND1 RS614367多态性与临床病理特征的关系

Q3 Pharmacology, Toxicology and Pharmaceutics

Biomedical and Pharmacology Journal Pub Date : 2023-08-30 DOI:10.13005/bpj/2765

Putu Anda Tusta Adiputra, I Gede Putu Supadmanaba, I Gede Krisna Arim Sadeva, Anak Agung Bagus Putra Indrakusuma, Putri Ayu Wulandari, Desak Made Wihandani

{"title":"病例报告:CCND1 RS614367多态性与临床病理特征的关系","authors":"Putu Anda Tusta Adiputra, I Gede Putu Supadmanaba, I Gede Krisna Arim Sadeva, Anak Agung Bagus Putra Indrakusuma, Putri Ayu Wulandari, Desak Made Wihandani","doi":"10.13005/bpj/2765","DOIUrl":null,"url":null,"abstract":"Recent studies have shown that the CCND1 rs614367 polymorphism increases the risk of breast cancer and its invasive nature. However, studies evaluating the relationship of the CCND1 rs614367 polymorphism based on the clinicopathology of breast cancer patients in Indonesia were still limited. This study is aimed to determine the CCND1 rs614367 polymorphism in breast cancer and its relationship with the patient's clinicopathology. Methods: This study was a cross-sectional study on 45 samples of breast cancer patients. After collecting demographic and clinical data, PCR and sequencing will be performed on all blood samples to determine the CCND1 rs614367 polymorphism. All variables that have been collected will be analyzed using SPSS version 25.0 to determine the relationship between the CCND1 rs614367 polymorphism and the clinicopathology of breast cancer patients. The CCND1 rs614367 gene polymorphism in breast cancer subjects showed that 25 (55.5%) and 20 (44.5%) subjects had C and T alleles. Subjects aged ≥ 50 years old had a significant 4.45 risk of having the T allele type (p=0.037). In addition, subjects with metastases (M1) were also at a significant 4.89 times risk of having the T allele type (p=0.015). Subjects with histological grade III also had a significantly 4.77 times risk of having the T allele type (p=0.013). In conclusion, there was a significant relationship between CCND1 rs614367 polymorphism and breast cancer subjects' clinopathology features (age, metastasis, and grade). More than half of the subjects with this polymorphism had the C allele.","PeriodicalId":9054,"journal":{"name":"Biomedical and Pharmacology Journal","volume":"29 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Case Report: The Relationship of CCND1 RS614367 Polymorphism with Clinicopathological Features\",\"authors\":\"Putu Anda Tusta Adiputra, I Gede Putu Supadmanaba, I Gede Krisna Arim Sadeva, Anak Agung Bagus Putra Indrakusuma, Putri Ayu Wulandari, Desak Made Wihandani\",\"doi\":\"10.13005/bpj/2765\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Recent studies have shown that the CCND1 rs614367 polymorphism increases the risk of breast cancer and its invasive nature. However, studies evaluating the relationship of the CCND1 rs614367 polymorphism based on the clinicopathology of breast cancer patients in Indonesia were still limited. This study is aimed to determine the CCND1 rs614367 polymorphism in breast cancer and its relationship with the patient's clinicopathology. Methods: This study was a cross-sectional study on 45 samples of breast cancer patients. After collecting demographic and clinical data, PCR and sequencing will be performed on all blood samples to determine the CCND1 rs614367 polymorphism. All variables that have been collected will be analyzed using SPSS version 25.0 to determine the relationship between the CCND1 rs614367 polymorphism and the clinicopathology of breast cancer patients. The CCND1 rs614367 gene polymorphism in breast cancer subjects showed that 25 (55.5%) and 20 (44.5%) subjects had C and T alleles. Subjects aged ≥ 50 years old had a significant 4.45 risk of having the T allele type (p=0.037). In addition, subjects with metastases (M1) were also at a significant 4.89 times risk of having the T allele type (p=0.015). Subjects with histological grade III also had a significantly 4.77 times risk of having the T allele type (p=0.013). In conclusion, there was a significant relationship between CCND1 rs614367 polymorphism and breast cancer subjects' clinopathology features (age, metastasis, and grade). More than half of the subjects with this polymorphism had the C allele.\",\"PeriodicalId\":9054,\"journal\":{\"name\":\"Biomedical and Pharmacology Journal\",\"volume\":\"29 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomedical and Pharmacology Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.13005/bpj/2765\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical and Pharmacology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.13005/bpj/2765","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

摘要

最近的研究表明，CCND1 rs614367多态性增加了乳腺癌的风险及其侵袭性。然而，基于印度尼西亚乳腺癌患者临床病理评估CCND1 rs614367多态性关系的研究仍然有限。本研究旨在确定乳腺癌中CCND1 rs614367多态性及其与患者临床病理的关系。方法:对45例乳腺癌患者进行横断面研究。收集人口统计学和临床资料后，对所有血液样本进行PCR和测序，以确定CCND1 rs614367多态性。收集到的所有变量将使用SPSS 25.0版本进行分析，以确定CCND1 rs614367多态性与乳腺癌患者临床病理的关系。乳腺癌患者CCND1 rs614367基因多态性显示，C和T等位基因分别为25例(55.5%)和20例(44.5%)。年龄≥50岁的受试者患T等位基因型的风险为4.45 (p=0.037)。此外，有转移(M1)的受试者患T等位基因型的风险也为4.89倍(p=0.015)。组织学分级为III级的受试者患T等位基因型的风险为4.77倍(p=0.013)。综上所述，CCND1 rs614367多态性与乳腺癌受试者的临床病理特征(年龄、转移、分级)存在显著相关性。超过一半以上具有这种多态性的受试者具有C等位基因。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Case Report: The Relationship of CCND1 RS614367 Polymorphism with Clinicopathological Features

Recent studies have shown that the CCND1 rs614367 polymorphism increases the risk of breast cancer and its invasive nature. However, studies evaluating the relationship of the CCND1 rs614367 polymorphism based on the clinicopathology of breast cancer patients in Indonesia were still limited. This study is aimed to determine the CCND1 rs614367 polymorphism in breast cancer and its relationship with the patient's clinicopathology. Methods: This study was a cross-sectional study on 45 samples of breast cancer patients. After collecting demographic and clinical data, PCR and sequencing will be performed on all blood samples to determine the CCND1 rs614367 polymorphism. All variables that have been collected will be analyzed using SPSS version 25.0 to determine the relationship between the CCND1 rs614367 polymorphism and the clinicopathology of breast cancer patients. The CCND1 rs614367 gene polymorphism in breast cancer subjects showed that 25 (55.5%) and 20 (44.5%) subjects had C and T alleles. Subjects aged ≥ 50 years old had a significant 4.45 risk of having the T allele type (p=0.037). In addition, subjects with metastases (M1) were also at a significant 4.89 times risk of having the T allele type (p=0.015). Subjects with histological grade III also had a significantly 4.77 times risk of having the T allele type (p=0.013). In conclusion, there was a significant relationship between CCND1 rs614367 polymorphism and breast cancer subjects' clinopathology features (age, metastasis, and grade). More than half of the subjects with this polymorphism had the C allele.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Biomedical and Pharmacology Journal Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

1.20

自引率

0.00%

发文量

189

期刊介绍： Biomedical and Pharmacology Journal (BPJ) is an International Peer Reviewed Research Journal in English language whose frequency is quarterly. The journal seeks to promote research, exchange of scientific information, consideration of regulatory mechanisms that affect drug development and utilization, and medical education. BPJ take much care in making your article published without much delay with your kind cooperation and support. Research papers, review articles, short communications, news are welcomed provided they demonstrate new findings of relevance to the field as a whole. All articles will be peer-reviewed and will find a place in Biomedical and Pharmacology Journal based on the merit and innovativeness of the research work. BPJ hopes that Researchers, Research scholars, Academician, Industrialists etc. would make use of this journal for the development of science and technology. Topics of interest include, but are not limited to: Biochemistry Genetics Microbiology and virology Molecular, cellular and cancer biology Neurosciences Pharmacology Drug Discovery Cardiovascular Pharmacology Neuropharmacology Molecular & Cellular Mechanisms Immunology & Inflammation Pharmacy.